・The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 nearing Phase 3. ・Pfizer’s BioNTech position was reduced by 54.7%, leaving ...

NEW YORK (Reuters) - The U.S. Food and Drug Administration is investigating around five allergic reactions that happened after people were administered Pfizer Inc and BioNTech SE's COVID-19 vaccine in ...

(Reuters) - There were no cases of severe allergic reactions to Pfizer Inc and partner BioNTech SE's COVID-19 vaccine candidate during clinical trials, a Pfizer executive said at a regulatory ...

Pfizer's revenue, earnings, and stock price dropped off a cliff due to its inability to sustain the incredible sales ...

"The public understandably has been concerned about reports of rare, severe allergic reactions to the Moderna and Pfizer-BioNTech COVID-19 vaccines," Dr. Anthony Fauci, director of the National ...

The National Institutes of Health is reportedly planning to conduct a clinical study to determine why people are having severe allergic reactions to Pfizer's COVID-19 vaccine. According to the ...

As 2026 begins, pharmaceutical giant Pfizer is navigating a complex landscape marked by both operational challenges and significant financial developments. The company's latest outlook has ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...